A new PET imaging approach that measures synaptic density in the spinal cord provides a quantitative way to assess the ...

Study data support SV2A PET as quantitative tool for monitoring synaptic pathology and evaluating future therapeutic ...

Stock Gains After Enrollment Milestone Reached Shares of Quantum BioPharma (NASDAQ:QNTM) rose 10% in premarket trading on Monday after the company announced that patient enrollment in its ...

A new study from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, suggests positron emission tomography (PET) brain scans could reveal hidden inflammation ...

Detailed price information for Quantum Biopharma Ltd (QNTM-Q) from The Globe and Mail including charting and trades.

SHREVEPORT, La. - The Center for Molecular Imaging and Therapy, a subsidiary of BRF, proudly announces its new collaboration with the Brain Health Alliance as an imaging site in the nationwide EPSMS ...

The trial includes 48 patients with non-active secondary progressive multiple sclerosis (na-SPMS) across the U.S. ・The ...

Enrollment has reached 50% in an ongoing study testing whether a PET tracer can reliably measure myelin damage in people with MS.

Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed) Foralumab to advance into Phase 2 human ...

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark, ...